

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
13 October 2005 (13.10.2005)

PCT

(10) International Publication Number  
**WO 2005/094880 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 39/395**,  
A61P 37/00, A61K 39/00

(21) International Application Number:  
PCT/CA2005/000472

(22) International Filing Date: 30 March 2005 (30.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/558,080 30 March 2004 (30.03.2004) US  
60/613,712 29 September 2004 (29.09.2004) US

(71) Applicant (for all designated States except US): CANA-  
DIAN BLOOD SERVICES [CA/CA]; 1800 Alta Vista  
Drive, Ottawa, Ontario K1G 4J5 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LAZARUS, Alan  
H. [CA/CA]; 49 Thorncliffe Park Dr., Suite 1705, Toronto,  
Ontario M4H 1J6 (CA). SIRAGAM, Vinayakumar


[CA/CA]; 800 Richmong Street West, #503, Toronto,  
Ontario M6J 3N8 (CA). BRINC, Davor [CA/CA]; 77  
Maitland Place, #505, Toronto, Ontario M4Y 2V6 (CA).  
FREEDMAN, John [CA/CA]; 44 Charles Street W.,  
#4405, Toronto, Ontario M4Y 1R8 (CA). SONG, Seng  
[CA/CA]; 37 Tristan Crescent, Toronto, Ontario M2H 1X2  
(CA). CROW, Andrew R. [CA/CA]; 1 Massey Square,  
#1217, East York, Ontario M4C 5L4 (CA).

(74) Agent: OGILVY RENAULT LLP/S.E.N.C.R.L., S.R.L.;  
Suite 1500, 45 O'Connor Street, Ottawa, Ontario K1P 1A4  
(CA).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,  
ZM, ZW.

[Continued on next page]

(54) Title: METHOD FOR TREATING AUTOIMMUNE DISEASES WITH ANTIBODIES



(57) Abstract: A method for treating autoimmune diseases in a mammal which method comprises administering to the mammal an effective amount of at least one antibody specific for a soluble antigen is provided. Furthermore, a novel mechanism of action has been established in accordance with the present invention for antibody-based treatment regimes for autoimmune disease, including but not limited to anti-CD44 and soluble antigen specific antibody treatment regimes.



(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

— *with international search report*

METHOD FOR TREATING AUTOIMMUNEDISEASES WITH ANTIBODIESTECHNICAL FIELD

This application relates to the treatment of autoimmune  
5 diseases using antibodies. More preferably, the present  
invention relates to treatment of autoimmune diseases with  
soluble antigen-specific antibodies.

BACKGROUND OF THE INVENTION

Immune thrombocytopenic purpura (ITP) is an autoimmune  
10 disease characterised by platelet clearance mediated by  
pathogenic anti-platelet antibodies. It has been previously  
suggested that this platelet clearance is mediated by Fcγ  
receptor (FcγR)-bearing macrophages in the reticuloendothelial  
system (RES). While intravenous immunoglobulin (IVIg) is  
15 widely used in the treatment of ITP as well as in a wide  
variety of chronic autoimmune and inflammatory diseases, its  
mechanism of action is not yet fully elucidated. Possible  
mechanisms of action include inhibition of RES function, anti-  
idiotype antibodies and immunomodulation. In murine models of  
20 ITP, it has been demonstrated that IVIg ameliorates ITP by a  
mechanism completely dependent upon the expression of the  
inhibitory FcγRIIB. In humans, there is also evidence that  
IVIg increases the level of expression of FcγRIIB. In  
addition, it has been previously reported that the clinical  
25 effects of IVIg as well as monoclonal mimetics of IVIg both  
ameliorate murine ITP in a manner that correlates with RES  
blockade. This 'competitive' RES blockade has long been  
considered to be the primary mechanism whereby IVIg  
ameliorates ITP.

The present study was undertaken to investigate if antibodies to soluble antigens could inhibit autoimmune diseases.

#### SUMMARY OF THE INVENTION

5       According to the present invention, a novel method for treating an autoimmune disease is provided. Furthermore, a novel mechanism of action has been established in accordance with the present invention for antibody-based treatment regimes for autoimmune disease, including, but not limited to  
10   anti-CD44 and soluble antigen specific antibody treatment regimes.

      In one embodiment of the invention there is provided a method for treating autoimmune diseases in a mammal which method comprises administering to the mammal an effective  
15   amount of at least one antibody specific for a soluble antigen.

      Different types of autoimmune diseases be treated by the method of the present invention. According to the present invention, an autoimmune disease includes, but is not limited  
20   to Immune thrombocytopenia, Immune cytopenia, Idiopathic thrombocytopenic purpura (ITP), Neuropathy, Chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barre syndrome (GBS), Kawasaki's disease, Dermatomyositis, SLE, Myasthenia gravis, Post-transfusion purpura, Rheumatoid  
25   arthritis, Inflammatory arthritis, Eaton-Lambert syndrome, toxic epidermal necrolysis, and polymyositis.

      In one embodiment, the treatment can be effected for a time and under conditions sufficient to inhibit platelet  
30   clearance, thereby treating or ameliorating an autoimmune disease such as immune thrombocytopenic purpura (ITP), for example. In a further embodiment, inflammatory arthritis can

be prevented or ameliorated by the administration of antibodies to a soluble antigen in accordance with the present invention.

The soluble antigen can either be an endogenous or a foreign antigen. By foreign antigen it is meant an antigen that is not normally produced by the same individual or species. The antigen can be a non-functional/inert antigen. In an other embodiment the binding of the antibody to the antigen does not compromise the function of the antigen.

In an aspect of the invention the soluble foreign antigen and the antibody can be incubated together to form antibody-antigen complexes prior to administering the complexes to the mammal.

In another aspect of the invention, the endogenous soluble antigen can be obtained from the mammal and incubated with the antibody to form antibody-antigen complexes, the complexes being subsequently administered to the mammal. Alternatively, a soluble antigen may be injected into a mammal having a pre-existing antibody of interest specific to the soluble antigen, e.g. a mammal who has been previously immunised to tetanus toxin (any # of years earlier) may be administered an injection of soluble tetanus toxin according to an alternate embodiment of the present invention.

The antibody can be administered intravenously, interperitoneally, intradermally, intramuscularly, subcutaneously, orally or rectally.

In another embodiment of the invention, the soluble antigen can be associated with blood cells and the resulting antigen-cell complexes can be targeted by antibodies for inhibiting platelet clearance and thereby treating thrombocytopenia.

In another embodiment, an autoimmune disease treatment regime is provided to mediate a cellular response in dendritic cells, such as leukocytes, such that platelet clearance is slowed and/or inhibited, thereby treating or ameliorating an autoimmune disease.

In another aspect of the invention there is provided pharmaceutical compositions for treating autoimmune diseases such as arthritis and thrombocytopenia, comprising an effective amount of at least one antibody specific for a soluble antigen and/or for a soluble antigen associated with a blood cell.

In yet another aspect of the invention, an antibody to a soluble antigen may be used in the manufacture of a medicament for the treatment of an autoimmune disease.

In yet another aspect of the invention, we demonstrate herein that antibodies to soluble antigens can ameliorate ITP in an FcγRIIB-dependent manner. Antibody directed to the cell-associated antigen inhibited ITP in an FcγRIIB-independent manner. Taken together, these data demonstrate that IgG antibodies reactive with either a soluble or insoluble antigen can mimic the effects of IVIg. In addition, the mechanisms of action of these moieties are quite different: antibody reacted with soluble antigen may utilize the same pathway used by IVIg, i.e. an FcγRIIB-dependent pathway, whereas antibody reacted with a cell-associated antigen may work by additional and/or other mechanisms of action, and possibly by competitive RES inhibition.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

Further features and advantages of the present invention will become apparent from the following detailed

description, taken in combination with the appended drawings, in which:

Figs. 1A and 1B illustrate the association of OVA on the surface of RBCs.

5 Figs. 2A and 2B illustrates inhibition of thrombocytopenia by treating OVA-coupled RBCs with OVA-specific IgG.

10 Figs. 3A, 3B and 3C illustrates amelioration of thrombocytopenia with antibodies reactive with soluble OVA (in combination with soluble OVA) ameliorate immune thrombocytopenia.

Figs. 4A and 4B illustrates inhibition of RES function by antibodies reactive with soluble OVA (Fig. 4A) or OVA-RBCs (Fig. 4B).

15 Fig. 5 illustrates that antibodies reactive with soluble OVA or OVA-RBCs both ameliorate immune thrombocytopenia independent of complement activity.

20 Figs. 6A and 6B illustrate that FcγRIIB expression is required for reversal of immune thrombocytopenia by soluble OVA in the presence of anti-OVA.

Figs. 7A and 7B illustrate that FcγRIIB expression is not required for reversal of immune thrombocytopenia by cell-associated OVA in the presence of anti-OVA.

25 Figs. 8A and 8B illustrate that antibodies to endogenous soluble antigens ameliorate immune thrombocytopenia.

Fig. 9 illustrates that antibodies to albumin and transferrin require the expression of FcγRIIB to ameliorate immune thrombocytopenia.

Fig. 10 A and 10B illustrate that antibodies to albumin  
5 ameliorate K/BxN serum-induced inflammatory arthritis.

Fig. 11 illustrates IMCP-like effects shown by IVIg and anti-CD44 treatment regimes.

Fig. 12 illustrates IMCP-like effects as shown by IVIg and soluble antigen-specific antibody treatment regimes.

10 Fig. 13 illustrates IVIg-treated leukocytes showing therapeutic potential in the absence of FCγRIIB expression.

#### **DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT**

In this description by soluble antigen it is meant a  
15 molecule that can be incorporated and circulated in the blood stream. Examples of soluble antigens comprise but are not limited to: proteins, glycoproteins, lipids, glycolipids, peptides, nucleic acids, synthetic molecules or complexes or aggregates thereof.

20 By endogenous antigen it is meant antigens that occur naturally in a mammal and by foreign (or exogenous) antigen it is meant an antigen that is not normally produced by the same individual or species.

According to one embodiment of the present invention,  
25 antibodies to soluble antigens were tested for their ability to ameliorate autoimmune diseases. In one example, the amelioration of thrombocytopenia was tested. To address this question, a murine model of ITP was used to determine whether IgG specific to a soluble prototype antigen could prevent



thrombocytopenia. Mice injected with soluble ovalbumin (OVA) or OVA conjugated to RBCs (OVA-RBC) in the presence of anti-OVA, were both significantly protected from immune thrombocytopenia.

5 Both of these therapeutic regimes functioned independent of complement activity and both regimes also blocked reticuloendothelial function as assessed by clearance rates of fluorescent sensitized syngeneic RBCs. Soluble OVA or anti-OVA alone did not have any direct effect on immune  
10 thrombocytopenia in mice. It was found that OVA-RBC + anti-OVA ameliorated immune thrombocytopenia in normal mice, not in Fc $\gamma$ RIIB<sup>-/-</sup> mice, while soluble OVA + anti-OVA was ineffective. In addition, IgG specific for murine albumin and specific for transferrin also effectively inhibited ITP. Thus, IgG  
15 antibodies directed to soluble antigens can inhibit or reverse immune thrombocytopenia in an Fc $\gamma$ RIIB-dependent manner, whereas antibodies directed to a cell-associated antigen function independent of Fc $\gamma$ RIIB expression.

## Materials and Methods:

### 20 Reagents:

The monoclonal antibody specific for integrin  $\alpha_{IIb}$  (rat IgG<sub>1k</sub>, clone MWReg 30) was purchased from BD Pharmigen (Mississauga, ON, Canada). Monoclonal murine anti-OVA (IgG<sub>1</sub>, clone OVA-14), rabbit polyclonal anti-OVA, 1-ethyl-3-(3-dimethylamino-propyl) carbodiimide (EDAC), OVA (grade V), and  
25 PKH26 red fluorescent cell linker kit were purchased from Sigma (Oakville, ON, Canada). IVIG was Gamimune, 10% from Bayer (Elkhart, IN). Cobra Venom Factor (CVF), FITC-conjugated F(ab')<sub>2</sub> anti-rabbit IgG, and control rabbit IgG, were purchased  
30 from Cedarlane Laboratories Ltd (Hornby, ON, Canada). Rabbit anti-mouse albumin (IgG fraction), and rabbit anti-mouse transferrin (IgG fraction), were purchased from Research

Diagnostics (Flanders, NJ). Hemolysin (anti-SRBC rabbit serum) was supplied by Colorado Serum company (Denver, CO). Microdispenser tubes (250 µl) for blood collection were from VWR, (Mississauga, ON)

5 **Mice:**

Female CD1 mice (6-10 wks of age) were purchased from Charles River Laboratories (Montreal, PQ, Canada). C57BL/6 and FcγRIIB<sup>-/-</sup> (B6;129S4-*Fcgr2b*<sup>tm1<sup>Rav</sup></sup>/J) mice were purchased from the Jackson Laboratory (Bar Harbor, ME). All mice were housed in  
10 the St. Michael's Hospital Research Vivarium.

**Induction and treatment of immune thrombocytopenia:**

Mice were rendered thrombocytopenic by intraperitoneal injection of 2 µg anti-platelet (anti-integrin  $\alpha_{IIb}$ ) antibody in 200 µl phosphate buffered saline (PBS), pH 7.2. ITP was  
15 induced by two protocols:

For experiments where the therapeutic intervention preceded the induction of immune thrombocytopenia (e.g. Figs 2, 3, 5), mice were first injected intravenously with the indicated therapeutic preparation (eg OVA-RBC sensitized with  
20 anti-OVA IgG), followed at 24 h by a single injection of anti-platelet antibody. Mice were bled for platelet enumeration after a further 24 h.

For experiments where the induction of immune thrombocytopenia preceded the therapeutic intervention (e.g.  
25 Figs 6-8), mice were injected daily (days 0-3) with anti-platelet antibody and then injected intravenously with the indicated therapeutic preparation (eg OVA-RBC sensitized with anti-OVA IgG) on day 2. Mice were bled daily and platelets counted as described below.

In experiments where we wished to avoid the possibility of the formation of "pre-formed" immune complexes, mice were injected intraperitoneally with soluble OVA only followed 4 hours later by OVA-specific antibody via the intravenous route. Mice injected with anti-albumin or anti-transferrin alone received 1 mg of antibody in a volume of 200  $\mu$ l on day 2. For all IVIg treatments, mice were injected intraperitoneally with 0.5 ml of 10 % IVIG (roughly equivalent to 2 g/kg body weight). Platelets were counted as follows:

10 Mouse blood (45  $\mu$ L) was collected via saphenous vein bleeding into microdispenser tubes preloaded with 5  $\mu$ l of 1% EDTA in PBS. Then, 50  $\mu$ l of this mouse blood was diluted in 450  $\mu$ l of 1% EDTA/PBS (1:10) and then further diluted to a final dilution of 1:12,000 in 1% ethylenediaminetetraacetic acid

15 (EDTA)/PBS. Platelets were enumerated on a flow rate-calibrated FACScan flow cytometer (Becton Dickinson, San Jose, CA) using forward scatter (FCS) versus side scatter (SSC) to gate platelets as previously described.

20 **Preparation of OVA-specific antibody pre-incubated with soluble OVA:**

1 mg OVA was dissolved in 300  $\mu$ l PBS and was incubated with the indicated dose (Fig. 3A, 3B x-axes) of OVA-specific antibody (rabbit polyclonal or mouse monoclonal) for 1 hr at 37°C. The solution was then injected intravenously in a 300 $\mu$ l

25 volume. In separate experiments the OVA and antibody solution was incubated as above for 1 hour at 37°C and macromolecular immune complexes removed by centrifugation at 16,000xg at 4°C for 1 h followed by filtration of the resulting supernatant fluid using a 0.2  $\mu$ m filter (Filtropur S plus 0.2, Sarstedt,

30 Montreal, PQ). The pellet was resuspended in 300  $\mu$ l PBS and intravenously injected as above.

**Preparation of OVA-coupled RBCs:**

OVA was coupled to RBCs as follows: RBCs were resuspended at  $2.5 \times 10^8$ /mL in 5 mg/mL OVA in saline and 1.9 mg/mL 1-ethyl-3-(3-dimethylamino-propyl) carbodiimide (EDAC) was added. Following a 1 hr incubation at 4°C, the cells were washed once with a 2 mg/mL solution of OVA in PBS followed by one wash in PBS. To confirm the presence of OVA on RBCs, OVA coupled RBCs were incubated with 17 µg/mL rabbit polyclonal anti-OVA, washed, and then incubated with 8 µg/mL FITC conjugated F(ab')<sub>2</sub> anti-rabbit IgG. Cells were washed, resuspended in PBS, and analyzed by flow cytometry.

#### **Reticuloendothelial system (RES) blockade:**

RES blockade was assessed as follows: Whole blood (2 ml, diluted with 1/5 volume 1% EDTA in PBS) from unmanipulated SCID mice was pooled and centrifuged at 2,000 x g for 15 min to obtain 1 ml of packed erythrocytes. These packed erythrocytes were resuspended in 4 ml of PBS and incubated with 8 µg of anti-TER-119 antibody at 22°C for 30 min. The resulting opsonized erythrocytes were then washed twice with PBS and labeled with a fluorescent marker (PKH26 Kit, Sigma, St. Louis MO) according to the manufacturer's directions. Briefly, the opsonized erythrocytes were resuspended in 3 ml of PKH26 'diluent C' and mixed with another 4 ml of 'diluent C' containing 10 µl of the 'PKH26 linker'. After a 5 minute incubation with constant swirling, the mixture was incubated for 5 minutes with an equal volume of PBS containing 1% bovine serum albumin. The erythrocytes were washed 5 times and resuspended in 2 ml PBS. Mice were then injected via the tail vein with 200 µl of these labeled cells. All mice were bled via the tail vein at 3 min, 10 min, 30 min, 120 min, and 960 min post injection and the the total number of erythrocytes, as well as the percent of PKH26-fluorescent erythrocytes, were counted by flow cytometry. The percentage of labeled

erythrocytes at the 3 min time point was considered to be 100%.

**Complement depletion:**

Complement depleted mice were prepared by  
5 intraperitoneal injection of 5U of Cobra Venom Factor (CVF) in  
200  $\mu$ l phosphate-buffered saline pH 7.2 followed by a second  
injection of CVF after 4h. Complement depletion was confirmed  
by the complement hemolytic activity assay Briefly, sheep RBCs  
(SRBC) were washed in PBS and resuspended at  $1 \times 10^8$ /mL.  
10 Hemolysin (anti-SRBC rabbit serum) was diluted 1:50 and  
incubated with these sheep RBCs at 37°C for 30 min, washed in  
PBS and the cells incubated with a 1:10 dilution of mouse sera  
from control vs. CVF-treated mice at 37°C for 30 min. The  
mixture was then diluted with PBS, centrifuged at 1000 xg for  
15 5 min. Complement activity from the sera was assessed as  
follows: SRBC were resuspended in PBS at  $1 \times 10^8$ /mL. One mL of  
this was incubated with 1 mL of a 1/50 dilution of anti-SRBC  
antibody ('Hemolysin', Colorado serum, Denver, CO) and  
incubated for 30 min at 37°C. Cells were washed in PBS, and  
20 adjusted to  $1 \times 10^8$ /mL in PBS. Twenty mL of these cells were  
added to 20  $\mu$ l mouse serum from experimental mice in a 96 well  
flat bottom tissue culture plate for 30 min at 37°C. The plate  
was then centrifuged at 1,000 x g for 5 min, the supernatant  
was transferred to a new 96 well plate and the absorbance was  
25 read at 540 nm. Calculate percent hemolysis:  $100 \times$   
 $(OD_{540\text{sample}} - OD_{540\text{blank}}) / (OD_{540\text{max}} - OD_{540\text{blank}})$ . Calculate 50%  
lysis by plotting the log of serum dilution against log  
(%lysis/(100-%lysis)).

**Statistical analysis:**

30 Data was analyzed using the Student's t test, except  
data in Fig. 8, which was analyzed by one-way ANOVA. The level  
of significance was set at  $P < 0.05$ .

## Results

### Antibodies reactive with a cell-associated antigen can inhibit immune thrombocytopenia:

OVA-coupled murine RBCs (OVA-RBC) were assessed for reactivity with mouse (Fig. 1A) and rabbit (Fig. 1B) antibody specific to OVA by flow cytometry to ensure successful coupling of the OVA-RBCs. Figs. 1A and 1B illustrate the association of OVA on the surface of RBCs wherein OVA coupled RBCs are prepared with 1-ethyl-3-(3-dimethylamino-propyl) carbodiimide (EDAC) (Sigma Oakville, ON). OVA was coupled to RBCs as follows: RBCs were resuspended at  $2.5 \times 10^8$ /mL in 5 mg/mL OVA in saline and 1.9 mg/mL EDAC was added. Following a 1 hr incubation at 4°C, the cells were washed once with a 2 mg/mL solution of OVA in phosphate buffered saline (PBS), pH 7.2 followed by one wash in PBS. The OVA coupled RBCs were stained with rabbit (Fig. 1A) or mouse (Fig. 1B) polyclonal anti-OVA IgG (solid histogram), control rabbit (Fig. 1A) or mouse (Fig. 1B) IgG (solid line), followed by the appropriate FITC conjugated secondary antibody (dashed line, secondary antibody only) and wherein the x axis shows relative fluorescence intensity; y-axis represents cell number.

The monoclonal anti-OVA antibody employed in this study did react with OVA (as assessed by ELISA), but did not react with OVA-RBCs suggesting that the epitope recognized on OVA may be masked upon coupling with RBCs. Thus monoclonal anti-OVA was only used in treatments involving soluble OVA.

CD1 mice were injected intravenously with  $1 \times 10^8$  OVA-RBCs pre-incubated with nothing, OVA specific antibodies or an appropriate control IgG, 50 mg IVIg (roughly equivalent to 2g/kg body weight in a 25g mouse), or were left untreated. After 24 hours, all mice received anti-platelet antibody and all mice were bled for platelet enumeration after a further 24 h. Mice that received anti-platelet antibody alone became

thrombocytopenic (Figure 2, shaded horizontal bar), compared to unmanipulated control mice (Figure 2, dashed line). Figs. 2A and 2B illustrates inhibition of thrombocytopenia by treating OVA-coupled RBCs with OVA-specific IgG; CD1 mice were pre-injected intravenously with  $1 \times 10^8$  OVA-coupled RBCs pre-incubated with either rabbit (A) or mouse (B) OVA-specific polyclonal IgG, control IgG, or anti-OVA antibody, as indicated on the x axis. Mice in the IVIG groups received 50 mg IVIG. All mice (except 'Normal') received anti-platelet antibody one day later. Mice were bled for platelet enumeration after a further 24 h. Normal: The dashed line denotes the mean platelet count of non-injected mice; ITP: The horizontal bar denotes the mean platelet count ( $\pm 1$  SEM) of mice injected with anti-platelet antibody only. The x-axis indicates treatment; y-axis denotes platelet count; n=9 mice for each data point. \*\*\*  $P < 0.001$  vs. ITP mice. Data are represented as mean  $\pm$  SEM.

Mice treated with OVA-RBCs pre-incubated with either 50  $\mu$ g rabbit polyclonal anti-OVA (Figure 2A, 'OVA-RBC + anti-OVA') or 50  $\mu$ g murine polyclonal anti-OVA (Figure 2B, 'OVA-RBC + anti-OVA') were significantly protected from the development of immune thrombocytopenia compared with mice receiving OVA-RBCs alone (OVA-RBC) or OVA-RBC + control IgG (OVA-RBC + control IgG). The effectiveness of the IgG coated OVA-RBCs was comparable to that of IVIG (Figure 2A&B).

**Antibodies reactive with a soluble antigen can inhibit immune thrombocytopenia:**

CD1 mice were injected intravenously with 1 mg soluble OVA that had been pre-incubated with serial dilutions of the indicated amount of rabbit polyclonal anti-OVA (Figure 3A) or the indicated amount of murine monoclonal anti-OVA antibody (Figure 3B) one day prior to injection of anti-platelet antibody. Both of these therapeutic preparations ameliorated

immune thrombocytopenia (polyclonal anti-OVA at dosages of 1.0 or 0.5 mg/mouse, monoclonal at dosages of 50 or 10 ug/mouse).

CD1 mice were pre-injected intravenously with 1 mg OVA pre-incubated with the dose of rabbit polyclonal anti-OVA (A), or  
5 mouse monoclonal anti-OVA (B), as indicated on the x axis. Mice in the IVIG groups received 50 mg IVIG. The induction of thrombocytopenia and platelet counting were as in Figure 2. Panel C: the OVA/polyclonal anti-OVA solution was centrifuged and the supernatant fluid filtered using a 0.2 um filter to  
10 remove macromolecular immune complexes. The pellet was resuspended in PBS. Mice were injected with the therapeutic preparations indicated on the x axis. The induction of thrombocytopenia, platelet counting, and axis legends are as in Fig 2. The number of mice for data point were n=15 (A, B),  
15 n=4 (C). \*\*\*  $P < 0.001$  vs. ITP mice. Data are represented as mean  $\pm$  SEM.

It is of interest to note that OVA incubated with 50 ug monoclonal anti-OVA was essentially as successful at inhibiting ITP as was a standard dose of IVIg (Fig 3B). Mice  
20 treated with soluble OVA alone (Figure 3A&B, 0.0 mg/mouse) or OVA + control IgG (data not shown) were not significantly protected from the development of immune thrombocytopenia. OVA by itself did not affect the platelet count at any dose tested (0.1 mg, 1 mg, 5 mg and 10 mg, data not shown). Similarly all  
25 of the anti-OVA antibodies, in the absence of OVA, did not inhibit immune thrombocytopenia (data not shown).

To determine if the OVA + anti-OVA preparation ameliorated immune thrombocytopenia due to the formation of large macromolecular immune complexes, we subjected the OVA +  
30 polyclonal anti-OVA preparation (1mg:1mg) to centrifugation at 16,800 xg for 1 hr. at 4°C and the resulting supernatant was then filtered through a 0.2 uM filter (Filtropur S plus 0.2,



Sarstedt, Montreal, PQ). Pretreatment of mice with the filtered supernatant, but not the dissolved pellet (the pellet was dissolved by resuspending the pellet in PBS, pH 7.2, back to the original volume), prior to injection of anti-platelet antibody protected mice from thrombocytopenia (Figure 3C), suggesting that the "active" fraction was soluble and less than 0.2  $\mu$ M in size.

**Antibodies reactive with soluble and a cell-associated soluble antigen both block RES function:**

To assess whether the therapeutic regimes under study inhibited RES function, we employed a variation of the classic RES blockade assay, analysing the clearance rate of fluorescently labelled syngeneic RBCs sensitised with a murine RBC-specific antibody (anti-TER-119). Mice were subjected to the indicated therapeutic treatments, and their ability to clear these intravenously injected labelled RBCs over time was analysed (Fig 4). For the soluble antigen studies, mice were injected with nothing, IVIg, OVA-anti-OVA, or control IgG alone for 24 h followed by sensitized fluorescent RBCs (Figure 4A). At the indicated times post sensitized-fluorescent-RBC injection, blood was sampled to assess the RBC clearance rate as a measure of RES function. Only IVIg and OVA-anti-OVA blocked sensitized RBC clearance. Similar results were obtained with murine anti-OVA in combination with soluble OVA (data not shown).

For the cell-associated antigen studies, mice were injected with nothing, IVIg, anti-OVA sensitized OVA-RBCs, or OVA-RBCs alone for 24 h followed by sensitized fluorescent RBCs (Figure 4B). Only IVIg and anti-OVA sensitized OVA-RBCs blocked sensitized-fluorescent-RBC clearance.

In accordance with Figures 4A and 4B, mice were either not pre-treated (O), pre-treated with IVIG ( $\square$ ), pre-treated

with 1 mg OVA pre-incubated with 1 mg rabbit anti-OVA ( $\Delta$ ), or pre-treated with 1 mg control IgG + 1 mg OVA ( $\nabla$ ), followed 24 hours later by intravenous injection with fluorescently labeled TER-119-opsonized syngeneic RBCs, prepared as follows:

5 Whole blood (2 ml, diluted with 1/5 volume 1% EDTA in PBS) from unmanipulated mice was pooled and centrifuged at 2,000 x g for 15 min to obtain 1 ml of packed erythrocytes. These packed erythrocytes were resuspended in 4 ml of PBS and incubated with 8  $\mu$ g of anti-TER-119 antibody at 22°C for 30

10 min. The resulting opsonized erythrocytes were then washed twice with PBS and labeled with a fluorescent marker (PKH26 Kit, Sigma, St. Louis MO) as follows: Briefly, the opsonized erythrocytes were resuspended in 3 ml of PKH26 'diluent C' and mixed with another 4 ml of 'diluent C' containing 10  $\mu$ l of the

15 'PKH26 linker'. After a 5 minute incubation with constant swirling, the mixture was incubated for 5 minutes with an equal volume of PBS containing 1% bovine serum albumin. The erythrocytes were washed 5 times and resuspended in 2 ml PBS. Mice were then injected via the tail vein with 200  $\mu$ l of these

20 labeled cells. All mice were bled via the tail vein at 3 min, 10 min, 30 min, 120 min, and 960 min post injection and the total number of erythrocytes, as well as the percent of PKH26-fluorescent erythrocytes, were counted by flow cytometry. The percentage of labeled erythrocytes at the 3 min time point was

25 considered to be 100%.

Blood samples were taken at the times indicated on the x axis and the percentage of fluorescent RBCs in the circulation assessed by flow cytometry (Fig. 4B), mice were either not pre-treated (O), pre-treated with IVIG ( $\square$ ), pre-

30 treated with anti-OVA sensitized OVA-RBCs ( $\Delta$ ), or pre-treated with OVA-RBCs only ( $\nabla$ ) followed 24 hours later with intravenous injection of fluorescently labelled TER-119-opsonized autologous RBCs.

**Antibodies reactive with soluble or cell-associated soluble antigen inhibit ITP independent of complement activity:**

To determine if complement was a contributing factor to the above therapies, mice were depleted of Complement using cobra factor venom (CVF) as described above in [46]. CVF successfully depleted complement from the treated mice as assessed in a hemolytic activity assay on day 3 post CVF-treatment (data not shown). Complement depleted mice developed thrombocytopenia to the same extent as normal mice (Figure 5, column set 2). Complement depleted and normal mice both responded to the protective effects of OVA + anti-OVA and OVA-RBC + anti-OVA (column sets 4 and 5 respectively) to the same extent. However, complement depleted mice responded to IVIg treatment with significantly higher platelet counts compared with normal mice.

As shown in Figure 5, antibodies reactive with soluble OVA or OVA-RBCs both ameliorate immune thrombocytopenia independent of complement activity wherein mice were injected with CVF to deplete complement or were left untreated. After 24 hours, mice were treated with the therapeutic preparations indicated on the x axis, the induction of thrombocytopenia and platelet counting were as in Fig 2, control: mice receiving no therapeutic pre-treatment; Nil: mice treated with anti-platelet antibody only; 'OVA + anti-OVA': mice pre-treated with OVA + anti-OVA, followed 24 hr later by injection of anti-platelet antibody. 'OVA-RBC + anti-OVA': mice pre-treated with OVA-RBC + anti-OVA, followed 24 hr later by injection of anti-platelet antibody.

**FcγRIIB expression is required for protection with antibodies reactive with soluble, but not a cell-associated antigen:**

Wild type and FcγRIIB<sup>-/-</sup> mice were injected daily with anti-platelet antibody (↑) to induce stable thrombocytopenia (Fig 6). Mice were then treated with IVIg, OVA + anti-OVA, or

control IgG + OVA on day 2. Treatment of mice with 2 g/kg IVIG as well as OVA + anti-OVA successfully reversed immune thrombocytopenia in wild type (Figure 6A), but neither ameliorated ITP in FcγRIIB<sup>-/-</sup> mice (Figure 6B). Mice treated  
5 with control IgG + OVA displayed no increase in platelet counts.

Figs. 6A and 6B illustrate that FcγRIIB expression is required for reversal of immune thrombocytopenia by soluble OVA in the presence of anti-OVA wherein wild type mice (Fig.  
10 6A) or mice genetically deficient for FcγRIIB (FcγRIIB<sup>-/-</sup>) mice (Fig. 6B) were injected with anti-platelet antibody on days 0 through 3 denoted by the arrow (↑), on day 2 (↓) mice were injected intraperitoneally with IVIG (□), or intravenously with OVA + anti-OVA antibody (Δ), or non-  
15 specific IgG + OVA (▼) and mice were bled daily for platelet counts ( $\times 10^9/L$ ).

In sharp contrast to the results in Fig 6, ITP was successfully reversed in normal mice (Figure 7A) and FcγRIIB<sup>-/-</sup> mice (Figure 7B) that were therapeutically treated with OVA-  
20 RBCs + anti-OVA. As expected, treatment of mice with OVA-RBCs alone did not increase platelet counts in thrombocytopenic mice. Figs. 7A and 7B illustrate that FcγRIIB expression is not required for reversal of immune thrombocytopenia by cell-associated OVA in the presence of anti-OVA wherein wild type  
25 mice (Fig. 7A) or FcγRIIB<sup>-/-</sup> mice (Fig. 7B) were injected with anti-platelet antibody on days 0 through 3 (↑), on day 2 (↓) mice were injected intraperitoneally with IVIG (□), or intravenously with anti-OVA sensitized OVA-RBCs (Δ), or OVA-RBCs alone.

**Preformation of immune complexes are not necessary for reversal of ITP:**

To determine if it is necessary to incubate antigen and antibody before injection to ameliorate the thrombocytopenia in our model, mice were pre-injected with either 1 mg or 10 mg of soluble OVA followed by 1 mg anti-OVA after 4h. Significant reversal of ITP was achieved with OVA specific IgG in mice that were previously treated with either 1mg or 10 mg of OVA (Figure 8A).

To determine if antibody to endogenous soluble antigens can also inhibit immune thrombocytopenia, thrombocytopenic mice were treated with 1 mg polyclonal anti-mouse albumin or 1 mg anti-mouse transferrin antibody on day 2. Both of these antibodies, but not control IgG, significantly ameliorated the immune thrombocytopenia (Figure 8B). As illustrated in Figs. 8A and 8B, antibodies to endogenous soluble antigens ameliorate immune thrombocytopenia wherein (Fig. 8A) mice were treated with IVIG only ( $\square$ ), 10 mg OVA ( $\Delta$ ), or 1 mg OVA ( $\circ$ ), followed four hours later by 1 mg OVA-specific IgG ( $\downarrow$ ) on day 2 and wherein thrombocytopenia and platelet counting were as in Fig 6 and wherein (Fig. 8B) mice were treated with IVIG ( $\square$ ), 1 mg anti-mouse albumin antibody ( $\blacktriangle$ ), 1 mg anti-mouse transferrin antibody ( $\circ$ ), or control IgG ( $\blacklozenge$ ).

In contrast, anti-mouse albumin and anti-mouse transferrin antibodies failed therapeutically in Fc $\gamma$ RIIB<sup>-/-</sup> mice, and did not reverse immune thrombocytopenia (Figure 9). Here, antibodies to albumin and transferrin require the expression of Fc $\gamma$ RIIB to ameliorate immune thrombocytopenia. Fc $\gamma$ RIIB<sup>-/-</sup> mice were injected with 2  $\mu$ g anti-platelet antibody on days 0 through 3 denoted by the arrow ( $\uparrow$ ). On day 2 ( $\downarrow$ ) mice were injected intraperitoneally with 50 mg IVIg ( $\square$ ), or

intravenously with 1 mg anti-albumin antibody ( $\Delta$ ), or 1 mg anti-transferrin antibody (O). Mice were bled daily for platelet counting; n=3 mice for each group. Data are presented as mean  $\pm$  SEM.

5           In another embodiment of the invention antibodies to soluble antigens were used to treat or ameliorate inflammatory arthritis.

### Material and methods

#### K/BxN Serum-induced arthritis and arthritis scoring:

10           For induction of arthritis, mice were given a single intraperitoneal injection of 600  $\mu$ l of diluted serum (diluted to 50% strength with PBS) as previously described by Akilesh et al (Akilesh, S., Petkova, S., Sproule, T.J., Shaffer, D.J., Christianson, G.J., and Roopenian, D. 2004. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. *J Clin Invest* 113:1328-1333.). An additional control group of mice were injected with only PBS instead of K/BxN serum. Ankle width was measured laterally across the joint with a caliper (Samona International, Canada). Arthritis was  
15 also clinically scored daily by an independent blinded observer. Each paw was scored as follows: 0, [unaffected], 1 [slight swelling], 2 [moderate swelling], 3 [severe swelling involving the entire paw (foot, digits, ankle)], and the overall score was calculated as the sum of individual scores  
20 for each paw as described by de Fougérolles et al (de Fougérolles, A.R., Sprague, A.G., Nickerson-Nutter, C.L., Chi-Rosso, G., Rennert, P.D., Gardner, H., Gotwals, P.J., Lobb, R.R., and Koteliensky, V.E. 2000. Regulation of inflammation by collagen-binding integrins  $\alpha$ 1 $\beta$ 1 and  $\alpha$ 2 $\beta$ 1 in  
25 models of hypersensitivity and arthritis. *J Clin Invest* 105:721-729.). Mice injected with anti-albumin or the IgG control received 1 mg of IgG intravenously in 200  $\mu$ l PBS four  
30

hours prior to the induction of arthritis. Mice injected with IVIg received 50 mg of IVIg by an intraperitoneal injection four hours prior to the induction of arthritis.

**IgG reactive with a soluble antigen can ameliorate arthritis:**

5 To further evaluate the therapeutic role of antibodies directed to a soluble antigens in the K/BxN serum-induced arthritis model, C57BL/6 mice were injected with 50 mg IVIg, 1 mg anti-albumin, 1 mg non-immune IgG, or nothing 4 hours prior to receiving K/BxN serum. An additional control group of mice  
10 were injected with only PBS in place of the K/BxN serum. Mice that received K/BxN serum alone, or K/BxN serum + non-immune IgG, developed joint swelling (Figure 10A and B). As shown in Figures 10A & B, antibodies to albumin ameliorate K/BxN serum-induced inflammatory arthritis. (A) Ankle width and (B)  
15 overall arthritis score following K/BxN serum-induced arthritis. C57BL/6 mice were injected on day 0 with K/BxN serum (○), IVIg + K/BxN serum (□), anti-albumin + K/BxN serum (▲), Non-immune IgG + K/BxN serum (◆), or treated with only PBS in place of K/BxN serum (▽). Data represented as the mean  
20 ± SEM; n=3 mice for each group.

IVIg and the anti-albumin treatment significantly ameliorated the arthritis as assessed by ankle width measurements as well as by clinical score as compared to mice that received K/BxN serum or K/BxN serum plus treatment with  
25 non-immune IgG (Figure 10A and B).

**Mechanism of Action:**

Our further investigation has also revealed surprising evidence for the mechanism of action of the treatment regimes as herein disclosed. In particular, we have established that  
30 antibody treatment regimes such as IVIg, a monoclonal antibody to CD44 antigen and anti-soluble immune complex antibodies (in the presence of the antigen) work to ameliorate autoimmune

disease via an antibody-mediated cellular programming mechanism, otherwise herein referred to as IMCP, of non-B and non-T cell leukocytes. In particular, we show that IVIg, monoclonal antibody to CD44 antigen and anti-soluble immune complex antibodies (in the presence of the antigen) can bind to leukocytes in vitro and upon transfer in vivo, can ameliorate ITP, for example. More specifically, IVIg, a monoclonal antibody to the CD44 antigen, and anti-soluble immune complex antibodies (in the presence of the antigen) ameliorate autoimmune disease by interacting with a non-B cell non-T cell leukocyte which then, upon transfer to a host with an autoimmune disease, ameliorates disease activity. We have found that the leukocyte which mediates these clinical effects co-purifies with cells, including a subset of intestinal epithelial lymphocytes and a subset of activated T-cells, expressing the CD11c cell surface antigen, a surface marker expressed on most dendritic cells [data not shown]. Thus, a novel mechanism of action for IVIg and IVIg-like treatment regimes for autoimmune disease is herein provided.

Furthermore, a common linking factor is established in that the expression of FCgamma RIIB inhibitory receptor on cells is shown in the treatment regimes for anti-CD44 and antibodies directed to a soluble antigens, as has been previously established for IVIg. Thus, providing evidence that a common mode of action is the basis for the treatment regimes of the present invention. Having established a common mechanism of action with IVIg, anti-CD44 antibody, we believe that an antibody for a soluble antigen, in accordance with the present invention, will have a similar therapeutic effect as IVIg or anti-CD44 antibody, in the treatment and/or amelioration of a plurality of autoimmune diseases. Accordingly, the embodiments of the present invention may be



extended to provide beneficial treatment regimes for the prevention and/or treatment of other autoimmune diseases.

## **Materials and Methods**

### **Mice:**

5 CD1 mice (female 6-10 wk of age) and severe combined immune deficient (SCID) virgin mice (female 6 to 8 weeks of age) were purchased from Charles River Laboratories (Montreal, PQ, Canada). C57BL/6, BALB/c, and FcγRIIB<sup>-/-</sup> mice were (female 8 to 12 weeks of age) were from the Jackson Laboratory (Bar Harbor, ME).

### **Reagents:**

The monoclonal antibody specific for integrin αIIb (rat IgG<sub>1k</sub>, clone MWReg 30) was purchased from BD Pharmingen (Mississauga, ON). Bovine serum albumin (BSA) was purchased from Sigma (Oakville, ON, Canada). The IVIg (Gamimune N, 10%) was from Bayer (Elkhart, IN). To neutralize the pH of the IVIg (in some experiments), both IVIg and BSA were dialysed against phosphate buffered saline (PBS) (pH 7.2) in 1:200 ratio for 18 hours at 4°C using 12-14 kDa cutoff dialysis tubing (Spectrum Laboratories Inc, Rancho Dominguez, CA) under sterile conditions. Microdispenser tubes (250 µL) for blood collection were from VWR. Complete RPMI-1640 was RPMI-1640 medium (Sigma, Oakville, ON, Canada) supplemented with 10% heat-inactivated fetal calf serum, 80 µg/ml streptomycin sulphate, 0.2 µg/ml amphotericin B, 80 U/ml penicillin G and 1.6 mM L-glutamine.

### **IVIg-Mediated Cellular Programming (IMCP):**

#### **30 Preparation of IMCP blood:**

Blood (400 µl, or as otherwise indicated) was collected in sterile PBS containing 1% EDTA (PBS/EDTA), washed and the

cell pellets resuspended in 25 mg/ml of IVIg or BSA in PBS/EDTA. After incubation for 20 min (or as otherwise indicated) at 37°C in a shaking incubator, the cells were washed 2x in Ca<sup>++</sup> and Mg<sup>++</sup> free PBS, resuspended in saline and immediately injected back into the original mice. For preparation of WBC-reduced blood cells, the collected blood was first centrifuged at 900 xg for 5 min at 4°C, the plasma and buffy coat fractions were discarded. The cell pellets were washed 3x in PBS and resuspended in 25 mg/ml of IVIg or BSA as described above.

#### **Preparation of IMCP splenic cells:**

Spleens from normal mice were removed, mechanically disrupted in 5 ml of complete RPMI-1640 medium, and then filtered through 70-µm nylon mesh strainer. Erythrocytes were lysed using 0.15 M NH<sub>4</sub>Cl, 10 mM KHC03, 0.1 mM Na<sub>2</sub> EDTA (ACK) lysis buffer and washed 2x in RPMI-1640. The cells (1.4x10<sup>6</sup>/ml) were incubated with 18 mg/ml dialyzed IVIg (IMCP) or BSA (IMCP-control), or the indicated concentration (x/ml) of anti-CD44 (Antibody clone KM-114 or IM7), or with 1 mg of ovalbumin that was pretreated with 50 µg monoclonal anti-ovalbumin (Clone OVA-14, antibody subclass IgG1, From Sigma), or 1 mg of ovalbumin that was pretreated with 50 µg normal mouse IgG (Catalogue # 10400, from Caltag) for 30 min at 37°C in RPMI-1640. The cells were then washed 2x in RPMI-1640, resuspended to 5x10<sup>6</sup>/ml and injected (200 µl) into the tail vein of recipient mice.

#### **Fixation:**

Pre-fixed cells: splenic leukocytes (2.5 x10<sup>6</sup>/ml) were fixed in 1% paraformaldehyde in PBS for 10 minutes, washed 2x in PBS and then incubated with IVIg or BSA for 30 min as described above.

Post-fixed cells: splenic leukocytes were first incubated with IVIg or BSA for 30 min as described above, washed 2x in PBS and then fixed in 1% paraformaldehyde in PBS. The cells were then washed 2x in PBS, resuspended at  $5 \times 10^6/\text{ml}$  and  
5 injected (200  $\mu\text{l}$ ) into the tail vein of recipient mice.

#### Radiation:

Splenic leukocytes ( $5 \times 10^6/\text{ml}$ ) were irradiated (2500 rads) using cell irradiator ( $\gamma$  source, Cs-137) and then incubated with IVIg or BSA as described above.

#### 10 Induction and treatment of ITP:

For the administration of IVIg, BSA, or IMPC-cells, mice were first injected intraperitoneally with 50 mg of IVIg, BSA (~equivalent to 2 g/kg body weight), IMPC cells, or control-IMCP cells. After 24 hrs, mice were rendered thrombocytopenic  
15 by the intraperitoneal injection of 2  $\mu\text{g}$  anti-CD41 (anti-integrin  $\alpha\text{IIb}$ ) antibody in 200  $\mu\text{L}$  PBS. Twenty-four hours later, mice were bled by the saphenous vein and the platelets were counted on a flow rate-calibrated FACScan flow cytometer (Becton Dickinson) as previously described in detail (Br. J.  
20 Haematol. 115:679-686, 2001; Blood. 101: 708-3713, 2003).

#### T cell purification:

T cells were purified from spleens by magnetic separation using a T cell negative selection kit (StemCell Technologies, Vancouver, BC) according to manufacturer's instructions.  
25 Briefly, splenocytes were prepared in  $\text{Ca}^{++}$  and  $\text{Mg}^{++}$  free PBS containing 2% heat-inactivated fetal calf serum and 5% normal rat serum at  $10^8$  nucleated cells/mL. Splenocytes were then incubated with T cell negative selection cocktail (containing antibodies to CD11b, CD45R, Ly-6G(Gr-1), TER 119) at 20  $\mu\text{l}/\text{mL}$ ,  
30 followed by biotin selection cocktail at 100  $\mu\text{l}/\text{mL}$ , and magnetic nanoparticles at 100  $\mu\text{l}/\text{mL}$ . All incubations were done

for 15 min at 4°C. The recovered cells were stained with anti-CD3-FITC (10 µg/mL) and anti-CD19-PE (4 µg/mL) for 30 min at 4°C, washed, and analyzed by a FACScan flow cytometer. The recovered cells were routinely >90% CD3+ and <1% CD19+.

5 B cell purification:

B cells were purified from the spleen by magnetic separation using a B cell negative selection kit (StemCell Technologies, Vancouver, BC) according to manufacturer's instructions. Briefly, splenocytes were prepared in Ca++ and Mg++ free PBS containing 2% heat-inactivated fetal calf serum and 5% normal rat serum at 10<sup>8</sup> nucleated cells/mL. Splenocytes were then incubated with mouse FcR blocker (anti-CD16/32) at 10 µl/mL, B cell negative selection cocktail (containing antibodies to CD4, CD8, CD11b, Ly-6G(Gr-1), TER 119) at 20 µl/mL, followed by biotin selection cocktail at 100 µl/mL, and magnetic nanoparticles at 100 µl/mL. All incubations were done for 15 min at 4°C. The recovered cells were stained with anti-CD3-FITC (10 µg/mL) and anti-CD19-PE (4 µg/mL) for 30 min at 4°C, washed, and analyzed by FACScan flow cytometer. The recovered cells were routinely >80% CD19+ and 10 % CD3+.

## Results

We found that leukocytes can be treated with IVIg in vitro, washed free of unbound IVIg, and when as little as 10<sup>6</sup> of these cells are injected into a mouse, an IVIg-like effect is observed (ie. rapid reversal of the autoimmune disease symptom, in ITP, thrombocytopenia). This effect is specifically observed with blood or splenic leukocytes, but not red blood cells. The leukocytes must also be biologically active (ie γ irradiated or paraformaldehyde fixed leukocytes do not work) indicating that simple passive transfer of the IVIg is not the mode of action. B and T cells are not required for this clinical effect of IVIg. Thus, we have strong

experimental evidence that the antibody-based treatment regimes of the present invention, induce a priming event in innate leukocytes which endows leukocytes with the ability to ameliorate or inhibit autoimmune disease, specifically in ITP, thrombocytopenia, or in inflammatory arthritis, joint inflammation. We call this effect "IVIg-mediated cellular programming" (IMCP). This term is intended to more broadly refer to an antibody-mediated cellular programming effect, however for simplicity reference is made to the IVIg example, and hence IMCP is used throughout without prejudice. It is not intended to restrict the effect to only IVIg treatment regimes.

A monoclonal antibody (anti-CD44) is also demonstrated to inhibit immune thrombocytopenia by the same mechanism (ie. an IMCP-like effect in Figure 12. Here, anti-CD44 + leukocytes were incubated for 30 min, unbound anti-CD44 was washed off, leukocytes were then injected into ITP mice, and an amelioration of thrombocytopenia resulted. Mice in the first column (Nil) were uninjected. Mice in the second column (ITP) were treated with anti-platelet antibody ( $\alpha$ CD41) only. On Day 1, mice in the third and fourth column (IMCP) were injected intravenously with splenic leukocytes (10<sup>6</sup>/mouse) that went through the IMCP process with IVIg or anti-CD44 for 30 min. On Day 2 mice in columns (second to fourth) were injected with 2  $\mu$ g anti-platelet antibody. On Day 3, all mice were bled for platelet enumeration as described (Blood 105:1546-1548, 2005).

Figure 13 illustrates an antibody-mediated cellular programming effect, herein referred to as IMCP, as mentioned above, at work in splenic leukocytes incubated with monoclonal anit-OVA, thus establishing a basis for the mode of action of the treatment regimes of the present invention. As illustrated, anti-ovalbumin + ovalbumin + leukocytes are

incubated for 30 min, unbound anti-ovalbumin and ovalbumin are washed off, and leukocytes are injected into ITP mice to provide ameliorating effect against thrombocytopenia in vivo. According to Figure 13, mice in the first column (Nil) were uninjected. Mice in the second column (ITP) were treated with anti-platelet antibody ( $\alpha$ CD41) only. On Day 1, mice in the third column (IVIg) were injected with 50 mg/ml of dialyzed IVIg. Mice in the fourth column were injected (i.v.) with 1 mg OVA that had been pre-incubated with 50  $\mu$ g of monoclonal anti-OVA (IgG1, clone OVA-14 Sigma). Mice in the fifth column were treated as in fourth column except with control mouse IgG (mouse IgG, Cat# 10400, Caltag) in place of monoclonal anti-OVA. Mice in the sixth column (IMCP) were injected intravenously with splenic leukocytes (106/mouse) that went through the IMCP process with dialyzed IVIg for 30 min. Mice in the seventh column were treated with splenic leukocytes (106/mouse) that went through IMCP process with 1 mg OVA that had been pre-incubated with 50  $\mu$ g of monoclonal anti-OVA for 30 min. Mice in the eighth column were treated as in seventh column except with control mouse IgG in place of monoclonal-anti-OVA. On Day 2, mice in columns (second to eighth) were injected with 2  $\mu$ g anti-platelet antibody. On Day 3, all mice were bled for platelet enumeration as described (Blood 102:558-560, 2003).

25

IVIg, anti-CD44 (KM-114), and antibody to soluble antigens (in the presence of the soluble antigen) cannot ameliorate thrombocytopenia in mice which are genetically deficient in the inhibitory Fc $\gamma$  receptor (Fc $\gamma$ RIIB). Interestingly, however, we show here that these same antibodies can, all ameliorate thrombocytopenia when they are pre-incubated with leukocytes isolated from mice that are genetically deficient in Fc $\gamma$ RIIB (Fc $\gamma$ RIIB<sup>-/-</sup>) and the Fc $\gamma$ RIIB<sup>-/-</sup>

30

leukocytes are injected into wild type mice. Thus, the IMCP effect as herein reported can work where leukocytes do not express an FcγRIIB receptor. Although, FcγRIIB receptor expression was required in the recipient in order to achieve IMCP. In the reverse of this experiment (where the leukocytes are from FcγRIIB<sup>+/+</sup> mice and the recipient mice are FcγRIIB<sup>-/-</sup>), again, IVIg, anti-CD44, and anti-soluble antigen (+ the antigen) all cannot ameliorate the thrombocytopenia (Figure 14). As shown in Figure 14, mice in the 1<sup>st</sup> column (Nil-BL/6) are uninjected C57BL/6 mice. Mice in the 2<sup>nd</sup> column (CD41-BL/6) were C57BL/6 mice treated with anti-platelet antibody (αCD41) only. Mice in the 8<sup>th</sup> column (Nil-RIIB) were uninjected FcγRIIB<sup>-/-</sup> mice. Mice in the 9<sup>th</sup> column (CD41-RIIB) were FcγRIIB<sup>-/-</sup> mice treated with anti-platelet antibody (αCD41) only. On Day 1, mice in the 3<sup>rd</sup> column (IVIg-BL/6) were injected with 50 mg/ml IVIg. Mice in the fourth column (IVIg-BL/6) were C57BL/6 mice injected intravenously with splenic leukocytes (10<sup>6</sup>/mouse) from C57BL/6 mice that went through the IMCP process with IVIg for 30 min. Mice in the 5<sup>th</sup> column (IVIg-RIIB) were FcγRIIB<sup>-/-</sup> mice injected intravenously with splenic leukocytes (10<sup>6</sup>/mouse) from C57BL/6 mice that went through the IMCP process with IVIg for 30 min. Mice in the 6<sup>th</sup> column (BSA-RIIB) were FcγRIIB<sup>-/-</sup> mice injected intravenously with splenic leukocytes (10<sup>6</sup>/mouse) from C57BL/6 mice that went through the IMCP process with BSA for 30 min. Mice in the 7<sup>th</sup> column (BSA-BL/6) were C57BL/6 mice injected intravenously with splenic leukocytes (10<sup>6</sup>/mouse) from C57BL/6 mice that went through the IMCP process with BSA for 30 min. Mice in the 10<sup>th</sup> column (IVIg-RIIB) were injected with 50 mg/ml IVIg. Mice in the 11<sup>th</sup> column (IVIg-BL/6) were C57BL/6 mice injected intravenously with splenic leukocytes (10<sup>6</sup>/mouse) from FcγRIIB<sup>-/-</sup> mice that went through the IMCP process with IVIg for 30 min. Mice in the 12<sup>th</sup> column (IVIg-RIIB) were FcγRIIB<sup>-/-</sup> mice

injected intravenously with splenic leukocytes ( $10^6$ /mouse) from Fc $\gamma$ RIIB<sup>-/-</sup> mice that went through the IMCP process with IVIg for 30 min. Mice in the 13<sup>th</sup> column (BSA-RIIB) were Fc $\gamma$ RIIB<sup>-/-</sup> mice injected intravenously with splenic leukocytes ( $10^6$ /mouse) from  
5 Fc $\gamma$ RIIB<sup>-/-</sup> mice that went through the IMCP process with BSA for 30 min. Mice in the 14<sup>th</sup> column (BSA-RIIB) were C57BL/6 mice injected intravenously with splenic leukocytes ( $10^6$ /mouse) from Fc $\gamma$ RIIB<sup>-/-</sup> mice that went through the IMCP process with BSA for 30 min. On Day 2, mice in columns (2<sup>nd</sup> to 7<sup>th</sup> and 9<sup>th</sup> to 14<sup>th</sup>,  
10 inclusive) were injected with 2  $\mu$ g anti-platelet antibody. On Day 3, all mice were bled for platelet enumeration as described in Blood 102:558-560, 2003 with the exception that mice were bled by the saphenous vein in accordance with this embodiment of the present invention.

15

We therefore conclude that IVIg, anti-CD44, and anti-soluble antigen (in the presence of the antigen) do not function by binding to the Fc $\gamma$ RIIB on the leukocyte but do all function by a highly related mechanism, which we refer to as  
20 an IVIg-mediated cellular programming mechanism, or IMCP. Furthermore, the cellular programming mechanism (IMCP) of the present invention establishes an underlying mode of action for antibody-based treatment regimes of the present invention that appears to be more accurate than the previously reported RES  
25 blockade mechanism.

## DISCUSSION

We have observed that antibodies to soluble antigens ameliorated both murine ITP as well as arthritis. Since the  
30 immunological mechanisms involved in both of these diseases is very different, i.e. phagocytosis of opsonized platelets in the spleen vs. joint destruction, our data demonstrate that the therapeutic effects of the anti-soluble-antigen regime work to ameliorate autoimmune disease, in general. In



addition to the effectiveness of this treatment regime in both ITP and arthritis treatment, we have also established an underlying mechanism of action for the anti-soluble-antigen regime that is common to that of IVIg (the standard therapy  
5 for a multitude of autoimmune diseases) and anti-CD44 antibody. That is, an antibody-mediated cellular programming effect, as illustrated with pre-incubated leukocytes. Thus, further supporting the potential of an anti-soluble-antigen treatment regime of the present invention in the treatment of  
10 a plurality of autoimmune diseases.

The above described antibodies and antibody-antigen and antibody-antigen-cell complexes can be incorporated in pharmaceutical compositions to be injected in the mammal. Such compositions may also comprise a pharmaceutically acceptable  
15 carrier as would be known in the art.

The compositions can be injected in the mammal by several routes of administration comprising intravenously, interperitoneally, intradermally, intramuscularly, subcutaneously, orally or rectally.

20 It will be appreciated by persons skilled in the art that other antigens and antibodies could also be used according to the above described method to achieve similar results. It will also be appreciated that the method and composition could be applied to mammals, other than mice and  
25 rabbits, such as humans.

The embodiment(s) of the invention described above is(are) intended to be exemplary only. The scope of the invention is therefore intended to be limited solely by the scope of the appended claims.

**I/WE CLAIM:**

1. A method for treating an autoimmune disease in a mammal which method comprises administering to said mammal an effective amount of at least one antibody specific for a soluble antigen.
2. The method as claimed in claim 1 wherein said soluble antigen is a foreign antigen.
3. The method as claimed in claim 2 wherein said soluble foreign antigen is administered to said mammal prior to administering said antibody.
4. The method as claimed in claim 2 wherein said soluble foreign antigen and said antibody are incubated together to form antibody-antigen complexes prior to administering said complexes to said mammal.
5. The method as claimed in claim 3 or 4 wherein said foreign antigen is ovalbumin.
6. The method as claimed in claim 5 wherein said antibody is monoclonal or polyclonal.
7. The method as claimed in claim 1 wherein said soluble antigen is endogenous.
8. The method as claimed in claim 7 wherein said endogenous soluble antigen is obtained from said mammal and incubated with said antibody to form antibody-antigen complexes, said complexes being administered to said mammal.

9. The method as claimed in claim 7 wherein said soluble endogenous antigen is selected from albumin and transferrin or a combination thereof.
10. The method as claimed in claim 9 wherein said antibody is a polyclonal antibody or monoclonal antibody.
11. The method as claimed in claim 1 wherein said mammal is a human or a non-human mammal.
12. The method according to claim 1, wherein said at least one antibody is administered intravenously, interperitoneally, intradermally, intramuscularly, subcutaneously, orally or rectally.
13. The method of claim 1 wherein said effective amount of at least one antibody specific for a soluble antigen is administered for a time and under conditions sufficient to inhibit platelet clearance.
14. The method of claim 1 wherein said autoimmune disease is selected from Immune thrombocytopenia, Immune cytopenia, Idiopathic thrombocytopenic purpura (ITP), Neuropathy, Chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barre syndrome (GBS), Kawasaki's disease, Dermatomyositis, SLE, Myasthenia gravis, Post-transfusion purpura, Rheumatoid arthritis, Inflammatory arthritis, Eaton-Lambert syndrome, toxic epidermal necrolysis, and polymyositis.
15. The method of claim 1 wherein said autoimmune disease is immune thrombocytopenia (ITP).

16. The method as claimed in claim 1 wherein said autoimmune disease is inflammatory arthritis.
17. A method of inhibiting platelet clearance in a patient in need thereof which comprises administering to the patient a therapeutic composition comprising a therapeutic amount of at least one antibody specific for a soluble antigen and a pharmaceutically acceptable carrier, said therapeutic amount being sufficient to inhibit platelet clearance in said patient.
18. The method of claim 17, wherein the therapeutic amount of the at least one antibody specific for a soluble antigen is administered ranges from about 0.1µg to about 1g per kg of body weight per day.
19. The method of claim 18, wherein the at least one antibody specific for a soluble antigen is administered for a time sufficient to therapeutically increase and maintain platelet cell counts.
20. The method as claimed in claim 17 wherein said soluble antigen is a foreign antigen.
21. The method as claimed in claim 20 wherein said soluble foreign antigen is administered to said mammal prior to administering said antibody.
22. The method as claimed in claim 20 wherein said soluble foreign antigen and said antibody are incubated together to form antibody-antigen or antibody-antigen-blood cell complexes prior to administering said complexes to said mammal.

23. The method as claimed in claim 20 wherein said foreign antigen is ovalbumin.
24. The method as claimed in claim 23 wherein said antibody is monoclonal or polyclonal.
25. The method as claimed in claim 17 wherein said soluble antigen is endogenous.
26. The method as claimed in claim 25 wherein said soluble endogenous antigen is selected from albumin and transferrin or a combination thereof.
27. The method as claimed in 25 wherein said endogenous soluble antigen is obtained from said mammal and incubated with said antibody to form antibody-antigen complexes, said complexes being administered to said mammal.
28. The method as claimed in claim 25 wherein said mammal is a human or a non-human mammal.
29. The method according to claim 25, wherein said at least one antibody is administered intravenously, interperitoneally, intradermally, intramuscularly, subcutaneously, orally or rectally.
30. A pharmaceutical composition for treating an autoimmune disease, comprising an effective amount of at least one antibody specific for a soluble antigen in combination with a pharmaceutically acceptable carrier.
31. The composition as claimed in claim 30, wherein said antibody is capable of inhibiting platelet clearance.


32. The composition as claimed in claim 30 wherein said soluble antigen is a foreign antigen.
33. The composition as claimed in claim 32 wherein said soluble foreign antigen is administered to said mammal prior to administering said antibody.
34. The composition as claimed in claim 32 wherein said soluble foreign antigen and said antibody are incubated together to form antibody-antigen or antibody-antigen-blood cell complexes prior to administering said complexes to said mammal.
35. The composition as claimed in claim 32 wherein said foreign antigen is ovalbumin.
36. The composition as claimed in claim 35 wherein said antibody is monoclonal or polyclonal.
37. The composition as claimed in claim 32 wherein said soluble antigen is endogenous.
38. The composition as claimed in claim 32 wherein said soluble endogenous antigen is selected from albumin and transferrin or a combination thereof.
39. The composition as claimed in 32 wherein said endogenous soluble antigen is obtained from said mammal and incubated with said antibody to form antibody-antigen complexes, said complexes being administered to said mammal.
40. The composition as claimed in claim 39 wherein said mammal is a human or a non-human mammal.

41. The composition according to claim 39, wherein said at least one antibody is administered intravenously, intradermally, interperitoneally, intramuscularly, subcutaneously, orally or rectally.
42. The composition as claimed in claim 39, wherein said antibody is capable of inhibiting platelet clearance.
43. A pharmaceutical composition for treating an autoimmune disease, comprising an effective amount of at least one antibody specific for a soluble antigen in combination with a pharmaceutically acceptable carrier.
44. The use of at least one antibody specific for a soluble antigen for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of an autoimmune disease.
45. The use of claim 44 wherein said medicament comprises an therapeutic amount of said at least one antibody specific for a soluble antigen effective to slow and/or inhibit platelet clearance when administered to a patient in need thereof.
46. The use of claim 45 wherein the therapeutic amount of the at least one antibody specific for a soluble antigen is administered ranges from about 0.1µg to about 1g per kg of body weight per day.
47. The use as claimed in claim 44 wherein said soluble antigen is a foreign antigen.
48. The use as claimed in claim 47 wherein said soluble foreign antigen is administered to said mammal prior to administering said antibody.


49. The use as claimed in claim 47 wherein said soluble foreign antigen and said antibody are incubated together to form antibody-antigen or antibody-antigen-blood cell complexes prior to administering said complexes to said mammal.
50. The use as claimed in claim 47 wherein said foreign antigen is ovalbumin.
51. The use as claimed in claim 45 wherein said antibody is monoclonal or polyclonal.
52. The use as claimed in claim 45 wherein said soluble antigen is endogenous.
53. The use as claimed in claim 52 wherein said soluble endogenous antigen is selected from albumin and transferrin or a combination thereof.
54. The use as claimed in 52 wherein said endogenous soluble antigen is obtained from said mammal and incubated with said antibody to form antibody-antigen complexes, said complexes being administered to said mammal.
55. The use as claimed in claim 52 wherein said mammal is a human or a non-human mammal.
56. The use according to claim 52, wherein said at least one antibody is administered intravenously, interperitoneally, intradermally, intramuscularly, subcutaneously, orally or rectally.



1/14

**A****Figure 1A**

2/14

**B****Figure 1B**

3/14




Figure 2

4/14

Platelet count x




Figure 3

5/14




Figure 4

6/14




Figure 5

7/14




Figure 6

8/14




Figure 7



9/14




Figure 8

10/14




Figure 9

11/14




Figure 10

12/14




Figure 11

13/14




Figure 12

14/14




Figure 13

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA2005/000472

A. CLASSIFICATION OF SUBJECT MATTER IPC(7): A61K 39/395, A61P 37/00, A61K 39/00				
B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols) IPC(7): A61K 39/395, A61P 37/00, A61K 39/00				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields				
Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used) Canadian Patent Database, DELPHION, USPTO, ESPACENET, PUBMED Autoimmune disease; immune thrombocytopenic purpura, ITP, thrombocytopenia, treatment, intravenous immunoglobulin, antibody; soluble antigen, anti-CD44, antibody antigen complex, ovalbumin, albumin, transferrin				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category	Citation of document, with indication, where appropriate, of the relevant	Relevant to claim No.		
X	WO 99/03495 A1 (AVRAHAM, H. and GROOPMAN J.E.) 28 January 1999 Abstract; page 2, line 10 to page 4 line 12; page 11, line 35 to page 12, line 23; and page 21, line 25 to page 22, line 14.	1, 2, 7, 11-15, 17-20, 25, 28-32, 37, 43-47, 51, 52, 55 and 56		
Y		4, 22, 27, 39-42, 49 and 54		
X	WO 02/40047 A2 (LAZARUS, A. et al.) 23 May 2002 Abstract; page 5, line 11 to page 6, line 16.	1, 7, 11-15, 17-19, 25, 28-31, 43-46, 51, 52, 55 and 56		
Y		27 and 54		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.				
<table border="0"> <tr> <td> <p>* Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </td> <td> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&amp;" document member of the same patent family</p> </td> </tr> </table>			<p>* Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&amp;" document member of the same patent family</p>
<p>* Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&amp;" document member of the same patent family</p>			
Date of the actual completion of the international search 8 June 2005 (08-06-05)		Date of mailing of the international search report 27 July 2005 (27-07-2005)		
Name and mailing address of the ISA/CA Canadian Intellectual Property Office Place du Portage I, C114 - 1st Floor, Box PCT 50 Victoria Street Gatineau, Quebec K1A 0C9 Facsimile No.: 001(819)953-2476		Authorized officer  Qianfa Chen (819) 994-1374		

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA2005/000472

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant	Relevant to claim No.
X	SONG, S. et al. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Blood. 1 May 2003. Vol.101, No.9, pages 3708-3713. Abstract; and page 3709, right column, line 19 to page 3711, right column, line 22; and Figures 1-5.	1, 7, 11-15, 17-19, 25, 28-31, 43-46, 51, 52, 55 and 56
Y		27 and 54
X	CA 2,253,058 A1 (MADIYALAKAN, R. et al.) 02 March 2000 Page 13, line 12 to page 16, line 5; Examples 1 and 2; and claims 1-4, 42 and 46-48.	1, 7, 8, 11-14, 16, 30, 34, 43 and 44
Y		4, 22, 27, 39-42, 49 and 54
X	WO 02/076384 A2 (SCHULTES, B. and NICODEMUS, C.F.) 3 October 2002 Page 10, line 24 to page 11, line 8; page 12, line 1 to page 16 line 14; and page 35, lines 13-25.	1, 7, 8, 11-14, 16, 30, 34, 43 and 44
Y		4, 22, 27, 39-42, 49 and 54
X, P	SIRAGAM, M. et al. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J Clin Invest. January 2005; Vol.115, No.1, pages 155-160. See entire document.	1-56
A	KUTER, D. and ROSENBERG, R.D. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood. 15 May 1995. Vol.85, No.10, pages 2720-2730. Abstract; and page 2722, left and right columns, bridging paragraph.	1-56
A	AIGNER, S. et al. CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J. September 1998. Vol.12, No.12, pages 1241-1251. Abstract; and page 1246, left column, last paragraph.	1-56
A	RISTAMÄKI, R. et al. Serum CD44 in malignant lymphoma: an association with treatment response. Blood. 1 July 1994. Vol.84, No.1, pages 238-243. Abstract; and page 238, right column, lines 15-17.	1-56



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA2005/000472

### Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of the first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons :

1. ☒ Claim Nos. : 1-29, 46, 48, 54 and 56  
because they relate to subject matter not required to be searched by this Authority, namely :  
  
Claims 1-29, 46, 48, 54 and 56, which encompass a method of treatment of the human/animal body, are not required to be searched by this Authority under Rule 39.1 (iv) PCT. Regardless, a search has been carried out and based on the alleged effects of the products defined.
2. ☐ Claim Nos. :  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically :
3. ☐ Claim Nos. :  
because they are dependant claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows :

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claim Nos. :
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim Nos. :

**Remark on Protest** ☐ The additional search fees were accompanied by the applicant's protest and, where the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.  
PCT/CA2005/000472

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
WO9903495 A1	28-01-1999	AU8383598 A	10-02-1999
		EP1003547 A1	31-05-2000
		US5980893 A	09-11-1999
WO0240047 A2	23-05-2002	AU2040402 A	27-05-2002
		CA2467781 A1	23-05-2002
		EP1370288 A2	17-12-2003
		US2004047862 A1	11-03-2004
CA2253058 A1	02-03-2000	AT233102T T	15-03-2003
		AU711270 B2	07-10-1999
		AU732505 B2	26-04-2001
		AU762699 B2	03-07-2003
		AU4159399 A	05-01-2000
		AU5658096 A	05-12-1997
		AU8143998 A	04-01-1999
		BR9612619 A	20-07-1999
		CA2253602 A1	20-11-1997
		CA2292912 A1	23-12-1998
		CA2333221 A1	23-12-1999
		CA2464947 A1	01-05-2003
		DE10297379T T5	14-10-2004
		DE69626423D D1	03-04-2003
		DE69626423T T2	18-03-2004
		DK910407T T3	16-06-2003
		EP0910407 A1	28-04-1999
		EP1009433 A1	21-06-2000
		EP1085902 A2	28-03-2001
		EP1297846 A1	02-04-2003
		ES2193240T T3	01-11-2003
		GB0409191D D0	26-05-2004
		HU9903770 A2	28-03-2000
		IL126803 A	23-11-2003
		IL139832D D0	10-02-2002
		JP3565351B2 B2	15-09-2004
		JP11509558T T	24-08-1999
		JP2002504154T T	05-02-2002
		JP2002518342T T	25-06-2002
		NO985304 A	13-11-1998
		NZ332588 A	24-11-2000
		NZ503032 A	30-11-2001
		NZ505174 A	01-03-2002
		NZ516264 A	26-04-2002
		PT910407T T	31-07-2003
		SI910407T T1	31-10-2003
		US6086873 A	11-07-2000
		US6241985 B1	05-06-2001
		US2001036457 A1	01-11-2001
		US2002048586 A1	25-04-2002
		US2005063976 A1	24-03-2005
		WO9742973 A1	20-11-1997
		WO9857661 A1	23-12-1998
		WO9965517 A2	23-12-1999
		WO03034977 A2	01-05-2003
		ZA9810275 A	12-06-2000
WO02076384 A2	03-10-2002	CA2441393 A1	03-10-2002
		DE10296942T T5	18-11-2004
		GB0324503D D0	26-11-2003
		US2005031619 A1	10-02-2005